Literature DB >> 30995869

Glycemic Status and Thromboembolic Risk in Patients With Atrial Fibrillation and Type 2 Diabetes Mellitus: A Danish Cohort Study.

Mia Vicki Fangel1, Peter Brønnum Nielsen2,3, Jette Kolding Kristensen1, Torben Bjerregaard Larsen2,3, Thure Filskov Overvad2,4, Gregory Y H Lip2,5, Martin Bach Jensen1.   

Abstract

Background Diabetes mellitus is associated with increased risk of stroke in patients with atrial fibrillation, and differences in glycemic status may affect this risk. We aimed to examine the effect of glycemic status evaluated by hemoglobin A1c (HbA1c) on the risk of thromboembolism among patients with atrial fibrillation and type 2 diabetes mellitus. Methods In this cohort study, we used data from Danish registries to identify patients with type 2 diabetes mellitus and incident nonvalvular atrial fibrillation in the period of May 1, 2005, through December 31, 2015. On the basis of the most recent HbA1c measurement before an incident atrial fibrillation diagnosis, patients were divided into the categories: HbA1c ≤48 mmol/mol, HbA1c=49-58 mmol/mol, and HbA1c >58 mmol/mol. Cox regression analysis was used to estimate hazard ratios for the outcome thromboembolism. Results The study population included 5386 patients with incident nonvalvular atrial fibrillation and type 2 diabetes mellitus. Compared with patients with HbA1c ≤48 mmol/mol, we observed a higher risk of thromboembolism among patients with HbA1c=49-58 mmol/mol (hazard ratio, 1.49; 95% CI, 1.09-2.05) and HbA1c >58 mmol/mol (hazard ratio, 1.59; 95% CI, 1.13-2.22) after adjusting for confounding factors. When stratified on diabetes mellitus duration, similar results were found among patients with diabetes mellitus duration of <10 years. Contrastingly, in patients with diabetes mellitus duration of ≥10 years, higher HbA1c levels were not associated with a higher risk of thromboembolism. Conclusions In patients with incident atrial fibrillation and type 2 diabetes mellitus, increasing levels of HbA1c were associated with a higher risk of thromboembolism. However, no association was found among patients with diabetes mellitus duration ≥10 years.

Entities:  

Keywords:  atrial fibrillation; diabetes mellitus; glucose; risk; thromboembolism

Mesh:

Substances:

Year:  2019        PMID: 30995869     DOI: 10.1161/CIRCEP.118.007030

Source DB:  PubMed          Journal:  Circ Arrhythm Electrophysiol        ISSN: 1941-3084


  12 in total

1.  Impact of Diabetes Mellitus on Stroke and Survival in Patients With Atrial Fibrillation.

Authors:  Sri Harsha Patlolla; Hon-Chi Lee; Peter A Noseworthy; Waldemar E Wysokinski; David O Hodge; Eddie L Greene; Bernard J Gersh; Rowlens M Melduni
Journal:  Am J Cardiol       Date:  2020-06-30       Impact factor: 2.778

2.  Association of Atrial Fibrillation with Diabetes Mellitus, High Risk Comorbidities.

Authors:  Leonida Gherasim Md PhD PhD
Journal:  Maedica (Bucur)       Date:  2022-03

3.  Prevalence and predictors of atrial fibrillation in Japanese patients with type 2 diabetes.

Authors:  Sachiko Otake; Asako Sato; Tetsuya Babazono
Journal:  Diabetol Int       Date:  2021-05-16

4.  Effect of SLGT2 Inhibitors on Patients with Atrial Fibrillation.

Authors:  Justin Haloot; Lucijana Krokar; Auroa Badin
Journal:  J Atr Fibrillation       Date:  2021-08-31

5.  Association of Diabetes Duration and Glycemic Control With Stroke Rate in Patients With Atrial Fibrillation and Diabetes: A Population-Based Cohort Study.

Authors:  Husam Abdel-Qadir; Madison Gunn; Iliana C Lega; Andrea Pang; Peter C Austin; Sheldon M Singh; Cynthia A Jackevicius; Karen Tu; Paul Dorian; Douglas S Lee; Dennis T Ko
Journal:  J Am Heart Assoc       Date:  2022-02-08       Impact factor: 6.106

6.  Association between Hemoglobin A1c and Stroke Risk in Patients with Type 2 Diabetes.

Authors:  Yun Shen; Lizheng Shi; Elizabeth Nauman; Peter Katzmarzyk; Eboni Price-Haywood; Alessandra Bazzano; Somesh Nigam; Gang Hu
Journal:  J Stroke       Date:  2020-01-31       Impact factor: 6.967

7.  Prognostic significance of diabetes mellitus in patients with atrial fibrillation.

Authors:  Andreas S Papazoglou; Anastasios Kartas; Athanasios Samaras; Ioannis Vouloagkas; Eleni Vrana; Dimitrios V Moysidis; Evangelos Akrivos; Georgios Kotzampasis; Amalia Baroutidou; Anastasios Papanastasiou; Evangelos Liampas; Michail Botis; Efstratios Karagiannidis; Nikolaos Stalikas; Haralambos Karvounis; Apostolos Tzikas; George Giannakoulas
Journal:  Cardiovasc Diabetol       Date:  2021-02-11       Impact factor: 9.951

8.  One-year clinical outcomes of anticoagulation therapy among Japanese patients with atrial fibrillation: The Hyogo AF Network (HAF-NET) Registry.

Authors:  Kiyohiro Hyogo; Akihiro Yoshida; Motoshi Takeuchi; Kunihiko Kiuchi; Koji Fukuzawa; Mitsuru Takami; Atsushi Kobori; Katsunori Okajima; Michio Odake; Toshio Okada; Akira Shimane; Yasuhiro Kawahara; Junichi Sekiya; Hiroshi Sano; Yasunori Ichikawa; Ken-Ichi Hirata
Journal:  J Arrhythm       Date:  2019-08-16

Review 9.  Type 2 Diabetes, Atrial Fibrillation, and Direct Oral Anticoagulation.

Authors:  Dana Prídavková; Matej Samoš; Tomáš Bolek; Ingrid Škorňová; Jana Žolková; Peter Kubisz; Ján Staško; Marián Mokáň
Journal:  J Diabetes Res       Date:  2019-12-06       Impact factor: 4.011

10.  Pharmacotherapy for diabetes and stroke risk: Results from ROCKET AF.

Authors:  Francis E Ugowe; Anne S Hellkamp; Allen Wang; Richard C Becker; Scott D Berkowitz; Günter Breithardt; Keith A A Fox; Jonathan L Halperin; Graeme J Hankey; Kenneth W Mahaffey; Christopher C Nessel; Daniel E Singer; Manesh R Patel; Jonathan P Piccini
Journal:  Heart Rhythm O2       Date:  2021-04-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.